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The diagnosis of idiopathic normal pressure hydrocephalus (iNPH) is still challenging. Alzheimer’s disease (AD), along with
vascular dementia, the most important diﬀerential diagnosis for iNPH, has several potential cerebrospinal ﬂuid (CSF) biomarkers
whichmighthelpintheselectionofpatientsforshunttreatment. Theaimofthisstudywastocompareabattery ofCSFbiomarkers
including well-known AD-related proteins with CSF from patients with suspected iNPH collected from the external lumbar
drainage test (ELD). A total of 35 patients with suspected iNPH patients were evaluated with ELD. CSF was collected in the
beginning of the test, and the concentrations of total tau, ptau181,A β42,N F L ,T N F - α,T G F β1, and VEGF were analysed by ELISA.
Twenty-six patientshada positive ELDresult—thatis,their gaitsymptomsimproved; 9patients hadnegative ELD. Thelevels ofall
analyzed CSF biomarkers were similar between the groups and none of them predicted the ELD result in these patients. Contrary
to expectations lumbar CSF TNF-α concentration was low in iNPH patients.
1.Introduction
Normal pressure hydrocephalus (NPH) is characterized by a
clinical triad of symptoms including cognitive impairment,
gait diﬃculty, and urinary incontinence along with ventric-
ular enlargement in brain imaging [1]. NPH is considered
as idiopathic (iNPH) when there are no known predisposing
factors such as subarachnoid haemorrhage or brain trauma
[1]. NPH can be treated by shunt [1] but the response rate
is highly sensitive for selection of patients [2, 3]. Alzheimer’s
disease (AD)is along with vascular dementia(VaD)the most
frequent diﬀerential diagnosis for iNPH [4].
Several supplementary diagnostic tests of cerebrospinal
ﬂuid (CSF) dynamics are used in the selection of patients
to shunt surgery. The CSF tap test or external lumbar
drainage test (ELD) can predict the shunt response with
high speciﬁcity and are widely used [5]. Infusion tests
where usually RingerR-solution is infused into CSF space
with simultaneous CSF pressure monitoring to calculate
outﬂow conductance or outﬂow resistance are also used
[6]. In addition, intracranial pressure monitoring alone [7]
or together with cortical brain biopsy to detect AD-related
pathological ﬁndings [4] has been suggested.
CSF biomarkers reﬂecting ongoing pathophysiological
processes might further help in the evaluation of patients
with suspected iNPH. Previous reviews have pointed out
several potential CSF biomarkers associated with NPH [8]
but all of them still requiring further veriﬁcation [9]. There
arenumerousexperimentalstudiesinbothacuteandchronic
hydrocephalus that provide translational evidence for the
role of metabolic changes and markers in parallel with
hydrocephalus and disturbed CSF dynamics, for example, as
reported by Kondziella et al. [10].
Several CSF proteins are potentially important in iNPH
or Alzheimer’s disease.
Tumour necrosis factor-α (TNF-α), a proinﬂammatory
cytokine, seems to be one of the most promising since up to
45-foldincreasedCSFconcentrationscomparedwith healthy
controlshavebeenobservedinNPHpriortotreatmentalong
with normalization after shunt [11]. However, the patients
with known aetiology that is secondary NPH were mixed2 International Journal of Alzheimer’s Disease
Table 1: Characteristics of the patients and CSF concentrations of the analyzed biomarkers.
Positive ELD Negative ELD P
N. patients 26 9
Median age at ELD (range) 74 (65–88) 77 (69–88) .29
Median age at onset (range) 71.5 (62–86) 75 (68–88) .14
Male/female 13/13 5/4 .77 (X2)
Gait (n)2 5 9 . 5 5 ( X2)
Cognition (n)2 1 9 . 1 6 ( X2)
Incontinence (n)1 46 . 5 0 ( X2)
Major symptom gait/cogn/inc 21/2/1 7/1/1 .72 (X2)
2c a s e sn . d . ∗
Shunt 25 1
Shunt response fair/good/exc 1/3/21 0/0/1
NFL pg/mL 1940∗∗± 2662 (280–>10000) 2046 ± 2886 (483–9306) .92
Total tau pg/mL 274 ± 358 (44–1860) 291 ± 283 (89–983) .90
Aβ1–42 pg/mL 250 ± 179 (31–765) 209 ± 120 (102–486) .52
Total tau/Aβ1–42 > 1.15 7 (27%) 4 (44%) .33 (X2)
p-Tau181 pg/mL 55 ± 45 (16–234) 53 ± 25 (24–95) .88
TNF-α pg/mL 0.7 ± 1.1 (0–4.9) 1.3 ± 1.4 (0–3.4) .16
TGFβ-1 pg/mL 61 ± 24 (29–146) 71 ± 62 (20–228) .52
VEGF pg/mL n.d.∗∗∗ n.d.∗∗∗
The values are given as mean±SD (range) unless otherwise stated.
∗not able to determine one major symptom.
∗∗ two cases with concentration >10 000pg/mL (10 000 used as a value and therefore the real mean value is expected to be higher.)
∗∗∗not determined due to low concentration.
ELD: external lumbar drainage test, NFL: neuroﬁlament light chain, t-tau: total tau, p-tau181: phosphorylated tau181,A β42:a m y l o i d - β1–42,T N F - α:t u m o u r
necrosis factor-α,T G F β1: transforming growth factor β1, and VEGF: vascular endothelial growth factor.
with idiopathic cases and no further studies on this marker
have been published in NPH.
Transforming growthfactor-β (TGF-β) is associated with
brain response to injury and inﬂammation, and increased
CSF TGF-β concentrations are reported in AD patients
[12]. Subarachnoid haemorrhage (SAH) increased TGF-β
concentrations and correlated with the risk of shunt-
dependenthydrocephalus[13]butiniNPHtheroleofTGF-β
is somewhat controversial [14, 15].
Neuroﬁlament protein is a marker of neurodegeneration
especially axonal injury, and clearly increased NFlight (NFL)
concentrations have been detected both in iNPH and sNPH
patients [16, 17].
Vascular endothelial growth factor (VEGF) is associated
with cerebral ischemia and has been correlated negatively
with neuroﬁlament heavy chain (NFh) protein in iNPH
patients and increased during ELD [18].
Increased total tau (t-tau) and phosphorylated-tau181 (p-
tau181) in CSF are associated with neurodegeneration and
AD [19]. In iNPH both normal [17]a n di n c r e a s e d[ 20] t-
tau concentrations have been observed. Decreased amyloid-
β42 (Aβ42) in CSF is associated with AD and indicates risk of
AD in mild cognitive impairment [21] but may be normal in
iNPH [22].
In the present study, we correlated the concentrations of
seven biomarkers, NFL, t-tau, p-tau181 Aβ42,T N F - α,T G F β1,
and VEGF in the CSF of 35 patients with suspected iNPH
with the result of the lumbar drainage test.
Table 2: Black Scale for assessmentof shunt outcome [3].
Excellent Resumed preillness activity without deﬁcit
Good Resumed preillness activity with deﬁcit,
improved in two or more categories
Fair Improved but did not return to previous work,
improved in one category
Transient Temporary major improvement
Poor No change or worsening
Dead Died within 6wk of surgery or as a
result of surgery
2.Materialand Methods
2.1. Study Series. This study includes 35 patients referred to
Brigham and Woman’s Hospital (BWH) Neurosurgery with
suspected idiopathic normal pressure hydrocephalus (iNPH)
according to clinical and radiological examination. Patient
characteristics are presented in Table 1. Patients with known
cause of NPH (sNPH) were excluded.
2.2. External Lumbar Drainage Test (ELD). All patients
were evaluated by standard previously described ELD [23]
between 2007 and 2010. Continuous drainage was applied
withtargetedCSFdrainagerateof5to10mL/h.Neurological
(including Folstein Mini-Mental Status Examination in
patients with cognitive symptoms) and physical therapyInternational Journal of Alzheimer’s Disease 3
Table 3: CSF biomarkers.
Protein Abbreviation Mean
detection limit Manufacturer
Neuroﬁlament
light chain NFL 31pg/mL
Uman
Diagnostics,
Ume˚ a, Sweden
Total tau t-tau 12pg/mL
Invitrogen,
Camarillo,Calif,
USA
Phosphorylated
tau181
p-tau181 10pg/mL
Invitrogen,
Camarillo,Calif,
USA
Amyloid-β1–42 Aβ42 10pg/mL
Invitrogen,
Camarillo,Calif,
USA
Tumour necrosis
factor α TNF-α 0.106pg/mL
Quantikine HS,
R&D Systems,
Minneapolis,
Minn, USA
Transforming
growth factor β1 TGFβ14 . 6 1 p g / m L
Quantikine HS,
R&D Systems,
Minneapolis,
Minn, USA
Vascular
endothelial
growth factor-165
VEGF 5pg/mL
Invitrogen,
Camarillo,Calif,
USA
NFL: neuroﬁlament light chain, t-tau: total tau, p-tau181: phosphorylated
tau181,A β42:a m y l o i d - β1–42,T N F - α:t u m o u rn e c r o s i sf a c t o r - α,T G F β1:
transforming growth factor β1, and VEGF: vascular endothelial growth
factor.
(including Timed Up and Go test—the patient was timed
while rising from a chair, walking 3m, turning around,
walking backto thechair, and sitting down)evaluations were
completed prior to drainage and daily until the end of the
test,which continuedfor a maximum of 5 days. If the patient
demonstrated documented improvement before 5 days or if
the patient experienced side eﬀects of drainage refractory to
conservativemeasures, thetrial wasconsideredcompleteand
the drain was removed. Criteria for positive ELD were 20%
improvement in objectively measured gait or cognition [23].
ELD test was negative in nine and positive in 26 patients.
2.3. Response to Shunt. Patients were shunted or not accord-
ing to ELD result. One patient was shunted despite of pri-
mary negative response but later noted subjective improve-
ment.
Clinical symptoms, history of any possible known cause
of NPH, and other neurological disorders were recorded as
well as clinically evaluated response for treatment in shunted
patients. Shunt response was graded according to BlackScale
(Table 2) as no response, fair, good, or excellent response
after 3-month followup. All shunted patients responded to
the treatment (Table 1).
2.4. CSF Analysis for Biomarkers. The cerebrospinal ﬂuid
(CSF) samples (4mL) were collected in the beginning of the
ELD immediately after the puncture, centrifuged, and stored
in polypropylene tube at −80◦C until analysis to ensure the
stability of the CSF biomarker levels during the storage.
Measurements of CSF were performed in BWH Neuro-
surgery laboratory using commercially available solid phase
sandwich enzyme-linked immunosorbent assays (ELISA)
according to the manufacturer’s protocol and blinded to
the ELD results (Table 3). All samples were analyzed as
duplicates.
2.5. Ethical Aspects. The study was approved by the Partners
Human Research Committee. Written informed consent was
obtained from all patients.
2.6. Statistical Analysis. The CSF concentrations of the
analyzed markers were compared between the positive
and negative ELD groups by independent samples t-test.
Dichotomized variables were compared by X2-test. Pearson’s
correlation coeﬃcients were calculated between the markers.
Statistical analyzes were performed using SPSS 17.0.
3.Results
The biomarker concentrations in the CSF of 26 patients with
a positive ELD result and nine patients with negative ELD
result are presented in Table 1. Nine patients had initially
negative ELD, and one of them was shunted with excellent
response. The levels of all analyzed CSF biomarkers were
similar between the groups, and none of them could predict
the ELD result in these patients.
NFL concentrations were increased similarly both in
patients with positive (range 280–>10000) and negative
(range 438–9306) ELD (Table 1).
TNF-αconcentrationwas equallylowaround 1pg/mL in
bothgroups(Table 1).In10casestheconcentrationwas even
under the mean detection limit (0.106pg/mL).
TGFβ1 concentrations were similar (mean 61 versus
71pg/mL, range 20–228, P = .52) in both groups (Table 1).
TGFβ1 concentration had positive correlation with t-tau
(r = 0.413, P = .014, Table 4).
Mean Aβ42 concentrations did not diﬀer signiﬁcantly
between the groups (250 versus 209pg/mL) (Table 1).
Mean t-tau concentration was 274pg/mL (range 44–
1860) in positive and 291 (range 89–983) in negative ELD
groups without signiﬁcant diﬀerence (P = .90, Table 1)
and increased with age (r = 0.38, P = .023, Table 4).
Alsop-tau181 concentrationswereequalbetweenpositiveand
negative ELD groups (55 versus 53pg/mL, P = .88, Table 1).
VEGF concentrations were under the detection limit
(5pg/mL) in all except two cases and therefore were not
included in the correlation analysis.
4.Discussion
The most important ﬁnding of this study is the unexpectedly
low CSF TNF-α concentrations observed in iNPH patients
andtheinabilityofCSFbiomarkerstopredicttheELDresult.
Using a standard commercial ELISA, the CSF TNF-α
levels between 0 and 5.0pg/mL—close to the standard4 International Journal of Alzheimer’s Disease
Table 4: Correlations between CSF biomarkers.
NFL t-Tau Aβ1–42 p-Tau181 TNF-α TGFβ1
Age −0.112 (0.52) 0.383∗ (0.023) 0.215 (0.22) 0.010 (0.95) 0.246 (0.15) −0.009 (0.96)
NFL 0.030 (0.86) −0.225 (0.19) 0.063 (0.71) 0.130 (0.46) −0.013 (0.94)
t-Tau 0.030 (0.86) −0.071 (0.69) 0.667∗ (<0.001) 0.143 (0.41) 0.413∗ (0.014)
Aβ1–42 −0.225 (0.19) −0.071 (0.69) −0.169 (0.33) −0.024 (0.89) −0.103 (0.56)
p-Tau181 0.063 (0.71) 0.667∗ (<0.001) −0.169 (0.33) −0.138 (0.43) 0.205 (0.24)
TNF-α 0.130 (0.46) 0.143 (0.41) −0.024 (0.89) −0.138 (0.43) 0.267 (0.12)
TGFβ1 −0.013 (0.94) 0.413∗ (0.014) −0.103 (0.56) 0.205 (0.24) 0.267 (0.12)
NFL: neuroﬁlament light chain, t-tau: total tau, p-tau181: phosphorylated tau181,A β42:a m y l o i d - β1–42,T N F - α:t u m o u rn e c r o s i sf a c t o r - α,a n dT G F β1:
transforming growth factor β1.
levels previously observed in serum (0.5–2.8pg/mL)—were
detected. Concentrations up to 700pg/mL would have been
expectedaccordingtoonepreviousstudy[11].Diﬀerencesin
sampling and analyzing processes (diﬀerent ELISA was used
in the previous study [11]) might have eﬀect on the results
although likely not crucial. The most probable explanation
could be that in the previous study [11] the idiopathic cases
were not separated from the secondary cases. This indicates
that the inﬂammatory reaction would be associated with
secondary NPH rather than idiopathic form.
Our study did not include healthy controls, and our
negativeresultonTNF-αshouldbereproducedinstudywere
NPH patients with possible known cause of the disease are
separated from idiopathic cases and compared with healthy
controls. It would also be very interesting to study the
possible role of inﬂammation in the formation of secondary
hydrocephalusforexampleafterSAHortrauma.Experimen-
talstudiesclearlyindicatetheincreased productionofTNF-α
as well as other proinﬂammatory cytokines due to accession
of blood products to CSF [24].
Notably increased TGFβ1 levels after SAH indicated
risk of persistent hydrocephalus [13]. We detected rather
low TGFβ1 levels (varied from 20 to 228pg/mL) in iNPH
patients contrary to a previous observation of increased
concentrations [14] but supporting other studies with low
concentrations [15]. Interestingly TGFβ1 levels correlated
with t-tau but not with the levels of other studied biomark-
ers. This is contrary to a previous study in AD patients and
controls where TGFβ1 levels correlated with Aβ42 but not
with tau [12]. This can be explained by diﬀerent patient
population and by rather small number of cases in both
studies. The clear correlation between p-tau181 and total tau
is expected since phosphorylated tau is an isoform included
into total tau. Interestingly only total tau correlated with
age and TGFβ1. The correlation analysis can be justiﬁed to
indicate obvious associations between diﬀerent biomarkers
but has to be interpreted cautiously because of low statistical
power due to rather small number of cases.
Equally increased CSF VEGF levels are detected both
in AD and VaD patients also correlating with TGFβ1l e v e l s
[25]. Decreased cerebral blood ﬂow associated with chronic
hydrocephalus potentially leads to hypoxia, which could
induce increased VEGF formation also in iNPH. In an
experimental study the increased CSF VEGF levels were
seen only in a short-term model of chronic hydrocephalus
but not in the long-term model [26]. Therefore low VEGF
concentrations detected here are not very surprising.
Based on studies comparing AD patients and healthy
subjects it could be expected that iNPH patients with
low Aβ42 and increased t-tau and/or p-tau might have
concomitant early AD or could be in the risk of developing
AD. CSF tau and Aβ42 protein levels might help in the
detection of the patients who have AD instead of NPH
or may have signiﬁcant risk for concomitant AD. The low
Aβ42 together with increased tau concentrations (t-tau/Aβ42
ratio >1.15) seems to indicate increased risk of AD [19].
Thus total tau/Aβ42 ratio over 1.15 could be a potential
cut-oﬀ limit for increased risk of AD [19] and according
to that one-third of the current iNPH patients diagnosed
by LDT would be in increased risk of future AD. However,
increased CSF tau and decreased Aβ42 could be detected
also in other neurodegenerative disorders than AD [27].
In any case, shunted iNPH patient with still progressing
amnestic cognitive impairment and the proﬁle of increased
t a ua n dd e c r e a s e dA β42 should be noted and managed
interdisciplinary with a thorough dementia workup.
Speciﬁc CSF biomarkers of iNPH indicating shunt
response and the possible “point of no return” in the
course of the disease would be valuable. Also indicators of
the long-term prognosis especially those predicting risk of
dementia despite of shunting would be useful. However, this
would need a battery of biomarkers and long-term follow-
up studies since causes of dementia in these patients are
variable from AD to dementia with vascular origin and
perhaps dementia due to iNPH itself. Markers indicating
possibility of AD are already available but their predictive
value of concomitant AD in iNPH patients still needs to be
shown in follow-up studies.
Currently there seems to be no CSF biomarker available
which couldclearlypredicttheresultoflumbarCSFdrainage
test. Itshould also be keptin mind thatthe sensitivity of ELD
is not 100% and as also in this series there can be patients
whobeneﬁtfromshuntdespitenegativetestresult.Therefore
we can not exclude the possibility that some of the markers
analyzed here could somehow predict response for shunt
treatmentincaseofnegativeELD.IntauandNFLthecurrent
results are in line with the previous study where they did not
correlate with outcome of shunt [28].International Journal of Alzheimer’s Disease 5
Further research is needed to evaluate the molecular
biological basis of idiopathic NPH and to obtain CSF
biomarkers for the clinical diagnosis of iNPH. New methods
may detect novel proteins to clarify the pathophysiology of
iNPH [29]. The CSF, blood, and even brain tissue samples
which are possible to obtain without signiﬁcant additional
risk for the patient during diagnosis and treatment of NPH
may be useful in diﬀerential diagnosis and further research
[4]. Also they can be useful for validation of less invasive
methodstodetectforexampleAβandotherpossiblemarkers
of neurodegeneration and help in the discovery of new
surrogate markers. Neurosurgeons are encouraged to collect
blood, CSF, and tissue samples for future biobanks with
detailed clinical characterisation of patients with careful
history taking and use of standardized outcome scales. It is
alsoobligatorytopresenttheresultsoftheanalysesseparately
in diﬀerent entities of NPH since idiopathic and secondary
forms of the disease have diﬀerent molecular biological
background. The secondary forms of NPH should also be
separated depending on the speciﬁc aetiology.
In conclusion the CSF biomarkers analyzed here could
not predict the ELD result. Contrary to the expectations
lumbar CSF TNF-α concentrations were low in iNPH
patients.
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